OSE Immuno: positive analysis presented at ATC congress
The data show the safety of the product used in combination, and the first signs of efficacy without an episode of acute rejection after one year of post-renal transplant follow-up in all patients in the study", explains Gilles Blancho, the study's principal investigator.
The results of our exploration of the safety profile of FR104/VEL-101 seem promising and encouraging for the continuation of phase 2 development in kidney transplant patients awaiting innovative solutions", he continues.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction